Last reviewed · How we verify
Gabitril (TIAGABINE)
Gabitril (Tiagabine) is a small molecule anti-epileptic agent developed by Cephalon, targeting the Sodium- and chloride-dependent GABA transporter 1. It was FDA approved in 1997 for the treatment of epilepsy characterized by intractable complex partial seizures and simple partial seizures. Gabitril is now off-patent with multiple generic manufacturers. The drug has a half-life of 10 hours and 90% bioavailability. It is used to increase the concentration of GABA in the brain, thereby reducing seizure activity.
At a glance
| Generic name | TIAGABINE |
|---|---|
| Sponsor | Cephalon |
| Drug class | Anti-epileptic Agent |
| Target | Sodium- and chloride-dependent GABA transporter 1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Partial seizures
Common side effects
- Abdominal Pain
- Pain (Unspecified)
- Vasodilation
- Nausea
- Diarrhea
- Vomiting
- Increased Appetite
- Mouth Ulceration
- Myasthenia
- Dizziness
- Asthenia
- Somnolence
Drug interactions
- Phenytoin
- Carbamazepine
- Valproate
- Phenobarbital or Primidone
- Carbamazepine (effect on tiagabine)
- Phenytoin (effect on tiagabine)
- Phenobarbital (Primidone) (effect on tiagabine)
- Valproate (effect on tiagabine)
- Cimetidine
- Theophylline
- Warfarin
- Digoxin
Key clinical trials
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Treating Schizophrenia by Correcting Abnormal Brain Development (PHASE3)
- Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder (PHASE3)
- A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice (PHASE4)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1,PHASE2)
- Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. (PHASE4)
- Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence (PHASE1)
- Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |